Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae

Infection and Immunity

Volumn 67, Issue 9, 1999, Pages 4720-4724

  Tu, Anh Hue T ^a   Fulgham, Robert L ^a   Mccrory, Mark A ^b   Briles, David E ^a   Szalai, Alexander J ^b  

^a University of Alabama at Birmingham   (United States)

^b The University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C5; PNEUMOCOCCAL SURFACE PROTEIN A; PROTEIN SUBUNIT; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL VIRULENCE; COLONY FORMING UNIT; COMPLEMENT ACTIVATION; COMPLEMENT BLOOD LEVEL; COMPLEMENT INHIBITION; CONTROLLED STUDY; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; REGULATORY MECHANISM; STRAIN DIFFERENCE; STREPTOCOCCUS PNEUMONIAE;

EID: 0032797913     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.67.9.4720-4724.1999     Document Type: Article

References (30)

1. Amsbaugh, D. F., C. T. Hansen, B. Prescot, P. W. Stashak, D. R. Barthold, and P. J. Baker. 1972. Genetic control of the antibody response to type III pneumococcal polysaccharide in mice. Evidence that an X-linked gene plays a decisive role in determining responsiveness. J. Exp. Med. 136:931-949.
2. Benton, K. A., J. C. Paton, and D. E. Briles. 1997. Differences in virulence for mice among Streptococcus pneumoniae strains of capsular types 2,3,4,5, and 6 are not attributable to differences in pneumolysin production. Infect. Immun. 65:1237-1244.
3. Bisno, A. L. 1979. Alternate complement pathway activation by group A streptococci: role of M-protein. Infect. Immun. 26:1172-1176.
4. Briles, D. E, C. Forman, J. C. Horowitz, J. E. Volanakis, W. H. Benjamin, Jr., L. S. McDaniel, J. Eldridge, and J. Brooks. 1989. Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens, Infect. Immun. 57:1457-1464.
5. Briles, D. E., S. K. Hollingshead, E. Swiatlo, A. Brooks-Walter, A. Szalai, A. Virolainen, L. S. McDaniel, K. A. Benton, P. C. Aerts, H. van Dijk, and M. J. Crain. Pneumococcal proteins PspA and PspC: their potential for use as vacines. In A. Tomasz and R. Austrian (ed.), Molecular biology of pneumococci and pneumococcal diseases, in press. Mary Ann Liebert Inc., Larchmont, N. Y.
6. Briles, D. E., M. Nahm, K. Schroer, J. Davie, P. Baker, J. Kearney, and R. Barletta. 1981. Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 Streptococcus pneumoniae. J. Exp. Med. 153:694-705.
7. Briles, D. E., R. C. Tart, E. Swiatlo, J. P. Dillard, P. Smith, K. A. Benton, B. A. Ralph, A. Brooks-Walter, M. J. Crain, S. K. Hollingshead, and L. S. McDaniel. 1998. Pneumococcal diversity: considerations for new vaccine strategies with an emphasis on pneumococcal surface protein A (PspA). Clin. Microbiol. Rev. 11:645-657.
8. Briles, D. E., J. Yother, and L. S. McDaniel. 1988. Role of pneumococcal surface protein A in the virulence of Streptococcus pneumoniae. Rev. Infect. Dis. 10:S372-S374.
9. Brown, E. J. 1985. Interaction of Gram-positive microorganisms with complement. Curr. Top. Microbiol. Immunol. 121:159-187.
10. Centers for Disease Control. 1989. Pneumococcal polysaccharide vaccine, recommendations of the immunization practices. Morbid. Mortal. Weekly Rep. 38:64-68.
11. Circolo, A., G. Garnier, W. Fukuda, X. Wang, T. Hidvegi, A. J. Szalai, D. E. Briles, J. E. Volanakis, R. A. Wetsel, and H. R. Colten. 1999. Genetic disruption of the murine complement C3 promoter region generates deficient mice with extra-hepatic expression of C3 mRNA. Immunopharmacology 42:135-149.
12. Crain, M. J., W. D. Waltman II, J. S. Turner, J. Yother, D. E. Talkington, L. M. McDaniel, B. M. Gray, and D. E. Briles. 1990. Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae. Infect. Immun. 58:3293-3299.
13. Edwards, M. S., D. L. Kasper, H. J. Jennings, and A. Nicholson-Weller. 1982. Capsular sialic acid prevents activation of the alternative complement pathway of type III, group B streptococci. J. Immunol. 128:1278-1283.
14. Parley, J. J., J. C. King, P. Nair, S. E. Hines, R. L. Tressler, and P. E. Vink. 1994. Invasive pneumococcal disease among infected and uninfected children of mothers with immunodeficiency virus infection. J. Pediatr. 124:853-858.
15. Fischetti, V. A., R. D. Horstmann, and V. Pancholi. 1995. Location of the complement factor H binding site on streptococcal M6 protein. Infect. Immun. 63:149-153.
16. Gordon, D. L., J. Rice, J. J. Finlay-Jones, P. J. McDonald, and M. K. Hostetter. 1988. Analysis of C3 deposition and degradation on bacterial surfaces after opsonization. J. Infect. Dis. 157:697-704.
17. Hammerschmidt, S., S. R. Talay, P. Brandtzaeg, and G. S. Chhatwal. 1997. SpsA, a novel pneumococcal surface protein with specific binding to secretory immunoglobulin A and secretory component. Mol. Microbiol. 25:1113-1124.
18. Hollingshead, S. K., R. S. Becker, and D. E. Briles. Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Unpublished data.
19. Johnsson, E., G. Andersson, G. Lindahl, and L.-O. Heden. 1994. Identification of the IgA-binding region in streptococcal protein Arp. J. Immunol. 153:3557-3564.
20. Matsumoto, M., W. Fukuda, A. Circolo, J. Goellner, J. Strauss-Schoenberger, X. Wang, S. Fujita, T. Hidvegi, D. D. Chaplin, and H. R. Colten. 1997. Abrogation of the alternative complement pathway by targeted deletion of murine factor B. Proc. Natl. Acad. Sci. USA 94:8720-8725.
21. McDaniel, L. S., G. Scott, J. F. Kearney, and D. E. Briles. 1984. Monoclonal antibodies against protease sensitive pneumococcal antigens can protect mice from fatal infection with Streptococcus pneumoniae. J. Exp. Med. 160: 386-397.
22. McDaniel, L. S., J. Yother, M. Vijayakumar, L. McGarry, W. R. Guild, and D. E. Briles. 1987. Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA). J. Exp. Med. 165:381-394.
23. Rosenow, C., P. Ryan, J. N. Weiser, S. Johnson, P. Fontan, A. Ortqvist, and H. R. Masure. 1997. Contribution of novel choline-binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae. Mol. Microbiol. 25:819-829.
24. Taktak, Y. S., and B. Stenning. 1992. Solid phase enzyme immunoassay for quantification of serum amyloid P (SAP) and complement component 3 (C3) proteins in acute-phase mouse sera. Horm. Metab. Res. 24:371-374.
25. Tart, R. C., L. S. McDaniel, B. A. Ralph, and D. E. Briles. 1996. Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice. J. Infect. Dis. 173:380-386.
26. Volanakis, J. E. 1998. The human complement system in health and disease, p. 9-32. In J. E. Volanakis and M. M. Frank (ed.), Overview of the complement system. Marcel Dekker, Inc., New York, N.Y.
27. Weiss, J. J., S. K. Law, R. P. Levine, and P. P. Cleary. 1985. Resistance to phagocytosis by group A streptococci: failure of deposited complement opsonins to interact with cellular receptors. J. Immunol. 134:500-505.
28. Wetsel, R. A., D. T. Fleischer, and D. L. Haviland. 1990. Deficiency of the murine fifth complement component (C5). A 2-base pair gene deletion in a 5′-exon. J. Biol. Chem. 265:2435-2440.
29. Winkelstein, J. A., A. S. Abramovitz, and A. Tomasz. 1980. Activation of C3 via the alternative complement pathway results in fixation of C3b to the pneumococcal cell wall. J. Immunol. 124:2502-2506.
30. Yother, J., G. L. Handsome, and D. E. Briles. 1992. Truncated forms of PspA that are secreted from Streptococcus pneumoniae and their use in functional studies and cloning of the pspA gene. J. Bacteriol. 174:610-618.